All courses
Banner pattern

RSV Protection for Infants

The National RSV Mother and Infant Protection Program (RSV-MIPP) provides free vaccines and antibodies to protect pregnant women and infants from respiratory syncytial virus (RSV).

Click here to find out more arrow icon

What is RSV?

Respiratory syncytial virus (RSV) is a common respiratory virus that infects the nose, throat, and lungs and is a leading cause of childhood hospitalisation.

Almost all infants will be infected with RSV before the age of 2, with around 12,000 babies every winter admitted to hospital with severe RSV.

The RSV - Mother and Infant Protection Program is available free for pregnant women and eligible infants. It prioritises uptake of the maternal Abrysvo® RSV vaccine.

The vaccine is available under the NIP for all women at 28–36 weeks pregnancy. This reduces the risk of severe RSV disease in infants under six months by around 70 per cent. It can safely be given with other pregnancy-recommended vaccines such as those for influenza, pertussis and COVID-19.

To protect infants most at risk from severe RSV disease, a complimentary program is available with a free long-acting RSV monoclonal antibody, Beyfortus™ (nirsevimab).

RSV monoclonal antibodies are recommended for:

  • young infants whose mothers did not receive RSV vaccine in pregnancy, or who were vaccinated less than 2 weeks before delivery
  • young infants who are at increased risk of severe RSV disease, regardless of their mother’s vaccination status
  • children who have medical risk factors for severe RSV disease in their 2nd RSV season.

eLearning Program

To support the RSV-MIPP, Benchmarque Group have designed a series of eLearning modules to meet the clinical needs of a range of key clinical groups including:

  • General Practitioners
  • Midwives
  • Hospital Specialists
  • Registered Nurses, Nurse Practitioners and other clinicians working as approved vaccine providers.

The RSV Protection for Infants module provides students with the skills and knowledge to work directly with families, parents and patients to increase understanding of RSV and the national program.

The eLearning modules aim to give participants:

  • A baseline understanding of RSV information
  • An understanding of safe storage, preparation, and administration of Beyfortus® (nirsevimab), ensuring adherence to best practice

Using scenarios and communication frameworks, participants will learn how to engage with parents and caregivers, and use evidence-based insights to deliver proactive, informed care that minimises the impact of RSV and supports families in making informed immunisation decisions.

Benchmarque Group has worked with a range of stakeholders external to develop the short 1-hour eLearning module.

This learning has been designed and developed by Benchmarque Group with funded support from Sanofi.

Start NOW

IQ Login
IQ Login